| irAEs | Immune-related adverse events |
| CTL | Cytotoxic T-lymphocyte |
| ICI | Immune checkpoint inhibitor |
| PFS | Progression-free survival |
| NSCLC | Non-small cell lung cancer |
| TME | tumor microenvironment |
| CRS | cytokine release syndrome |
| irAEs | Immune-related adverse events |
| CTL | Cytotoxic T-lymphocyte |
| ICI | Immune checkpoint inhibitor |
| PFS | Progression-free survival |
| NSCLC | Non-small cell lung cancer |
| TME | tumor microenvironment |
| CRS | cytokine release syndrome |